Heather J. Ribaudo

14.6k total citations
112 papers, 4.4k citations indexed

About

Heather J. Ribaudo is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Heather J. Ribaudo has authored 112 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Infectious Diseases, 57 papers in Virology and 51 papers in Emergency Medicine. Recurrent topics in Heather J. Ribaudo's work include HIV/AIDS drug development and treatment (62 papers), HIV Research and Treatment (57 papers) and HIV-related health complications and treatments (51 papers). Heather J. Ribaudo is often cited by papers focused on HIV/AIDS drug development and treatment (62 papers), HIV Research and Treatment (57 papers) and HIV-related health complications and treatments (51 papers). Heather J. Ribaudo collaborates with scholars based in United States, Spain and India. Heather J. Ribaudo's co-authors include Roy M. Gulick, Edward P. Acosta, Daniel R. Kuritzkes, David W. Haas, David B. Clifford, Judith S. Currier, Bruce R. Schackman, Cecilia M. Shikuma, G. Wilkinson and Catia Marzolini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Heather J. Ribaudo

105 papers receiving 4.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heather J. Ribaudo United States	34	3.2k	2.4k	1.6k	658	366	112	4.4k
Eugènia Negredo Spain	39	3.2k 1.0×	2.5k 1.1×	1.9k 1.2×	804 1.2×	170 0.5×	186	4.8k
Todd Hulgan United States	28	1.7k 0.5×	1.3k 0.5×	1.2k 0.7×	620 0.9×	199 0.5×	100	3.0k
Ferdinand W.N.M. Wit Netherlands	34	2.2k 0.7×	1.8k 0.8×	1.5k 0.9×	1.0k 1.5×	186 0.5×	109	3.6k
John R. Koethe United States	32	2.0k 0.6×	1.1k 0.5×	2.4k 1.5×	655 1.0×	144 0.4×	140	3.6k
Jacqueline Neuhaus United States	24	2.2k 0.7×	1.9k 0.8×	2.8k 1.7×	981 1.5×	54 0.1×	38	4.2k
Jennifer J. Kiser United States	32	2.5k 0.8×	1.1k 0.4×	403 0.3×	1.3k 2.0×	359 1.0×	107	3.5k
Stefano Zona Italy	28	1.3k 0.4×	666 0.3×	1.8k 1.1×	1.4k 2.1×	85 0.2×	85	3.6k
Leo B. Hurley United States	30	1.9k 0.6×	848 0.4×	919 0.6×	1.7k 2.7×	47 0.1×	71	3.7k
Janet P. Tate United States	31	1.2k 0.4×	313 0.1×	939 0.6×	1.6k 2.4×	200 0.5×	107	3.5k
Camlin Tierney United States	21	1.7k 0.5×	1.2k 0.5×	899 0.6×	383 0.6×	200 0.5×	60	2.4k

Countries citing papers authored by Heather J. Ribaudo

Since Specialization

Citations

This map shows the geographic impact of Heather J. Ribaudo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather J. Ribaudo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather J. Ribaudo more than expected).

Fields of papers citing papers by Heather J. Ribaudo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather J. Ribaudo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather J. Ribaudo. The network helps show where Heather J. Ribaudo may publish in the future.

Co-authorship network of co-authors of Heather J. Ribaudo

This figure shows the co-authorship network connecting the top 25 collaborators of Heather J. Ribaudo. A scholar is included among the top collaborators of Heather J. Ribaudo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather J. Ribaudo. Heather J. Ribaudo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grinspoon, Steven, Markella V. Zanni, Virginia A. Triant, et al.. (2025). Performance of the pooled cohort equations and D:A:D risk scores among individuals with HIV in a global cardiovascular disease prevention trial: a cohort study leveraging data from REPRIEVE. The Lancet HIV. 12(2). e118–e129. 9 indexed citations

Smith, Emma, Carlos Malvestutto, Heather J. Ribaudo, et al.. (2025). Cardiovascular Hazards of Abacavir- Versus Tenofovir-Containing Antiretroviral Therapies: Insights From an Analysis of the REPRIEVE Trial Cohort. Open Forum Infectious Diseases. 12(4). ofaf177–ofaf177.

Grinspoon, Steven, Estebán Martínez, Carl J. Fichtenbaum, et al.. (2025). Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2. Clinical Infectious Diseases. 82(2). e248–e257.

Lu, Michael T., Heather J. Ribaudo, Sara McCallum, et al.. (2025). Coronary Plaque, Inflammation, Subclinical Myocardial Injury, and Major Adverse Cardiovascular Events in the REPRIEVE Substudy. JACC Advances. 4(6). 101781–101781. 1 indexed citations

Kolossváry, Márton, Irini Sereti, Markella V. Zanni, et al.. (2025). Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV. Journal of Clinical Investigation. 135(22).

Smith, Emma, Pamela S. Douglas, Sara McCallum, et al.. (2025). Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings. Clinical Infectious Diseases. 82(1). e89–e92. 1 indexed citations

deFilippi, Christopher R., Sara McCallum, Markella V. Zanni, et al.. (2024). Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV. SHILAP Revista de lepidopterología. 3(9). 101206–101206. 3 indexed citations

Bhattacharya, Romit, Md Mesbah Uddin, Aniruddh P. Patel, et al.. (2024). Risk factors for clonal hematopoiesis of indeterminate potential in people with HIV: a report from the REPRIEVE trial. Blood Advances. 8(4). 959–967. 5 indexed citations

Erlandson, Kristine M., Triin Umbleja, Heather J. Ribaudo, et al.. (2024). Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function. Clinical Infectious Diseases. 80(2). 425–433. 1 indexed citations

10.

Kolossváry, Márton, Christopher R. deFilippi, Sara McCallum, et al.. (2023). Identification of pre-infection markers and differential plasma protein expression following SARS-CoV-2 infection in people living with HIV. EBioMedicine. 90. 104538–104538. 2 indexed citations

11.

Kolossváry, Márton, Christopher R. deFilippi, Michael T. Lu, et al.. (2022). Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. The Journal of Infectious Diseases. 226(10). 1809–1822. 9 indexed citations

12.

Lo, Janet, Carlos Malvestutto, Kathleen V. Fitch, et al.. (2021). Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. Open Forum Infectious Diseases. 8(12). ofab537–ofab537. 27 indexed citations

13.

Grinspoon, Steven, Kathleen V. Fitch, Edgar T. Overton, et al.. (2019). Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). American Heart Journal. 212. 23–35. 89 indexed citations

14.

Wilkin, Timothy, Christina M. Lalama, J. Gregory McKinnon, et al.. (2012). A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256. The Journal of Infectious Diseases. 206(4). 534–542. 60 indexed citations

15.

Rowley, Christopher F., Christian L. Boutwell, Esther J. Lee, et al.. (2010). Ultrasensitive Detection of Minor Drug-Resistant Variants for HIV After Nevirapine Exposure Using Allele-Specific PCR: Clinical Significance. AIDS Research and Human Retroviruses. 26(3). 293–300. 28 indexed citations

16.

Hammer, Scott M., Heather J. Ribaudo, Roland Bassett, et al.. (2010). A Randomized, Placebo-Controlled Trial of Abacavir Intensification in HIV-1–Infected Adults With Virologic Suppression on a Protease Inhibitor–Containing Regimen. HIV Clinical Trials. 11(6). 312–324. 16 indexed citations

17.

Shikuma, Cecilia M., Marshall J. Glesby, William A. Meyer, et al.. (2007). Metabolic Effects of Protease Inhibitor-Sparing Antiretroviral Regimens Given as Initial Treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). JAIDS Journal of Acquired Immune Deficiency Syndromes. 44(5). 540–550. 42 indexed citations

18.

Ribaudo, Heather J., David W. Haas, & Edward P. Acosta. (2006). Reply to Tong et al.. Clinical Infectious Diseases. 43(4). 542–544. 24 indexed citations

19.

Ribaudo, Heather J., David W. Haas, C. Tierney, et al.. (2006). Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases. 42(3). 401–407. 170 indexed citations

20.

Gulick, Roy M., Heather J. Ribaudo, Cecilia M. Shikuma, et al.. (2004). Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. New England Journal of Medicine. 350(18). 1850–1861. 396 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact